Compare BAND & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BAND | VNDA |
|---|---|---|
| Founded | 2000 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 395.6M | 474.0M |
| IPO Year | 2017 | 2005 |
| Metric | BAND | VNDA |
|---|---|---|
| Price | $20.42 | $7.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $20.40 | $14.90 |
| AVG Volume (30 Days) | 359.0K | ★ 1.5M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $204,113,000.00 | ★ $216,105,000.00 |
| Revenue This Year | $15.16 | $21.35 |
| Revenue Next Year | $6.18 | $37.40 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.26 | 8.72 |
| 52 Week Low | $11.33 | $3.81 |
| 52 Week High | $19.59 | $9.91 |
| Indicator | BAND | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 71.36 | 45.16 |
| Support Level | $13.20 | $7.12 |
| Resistance Level | N/A | $8.29 |
| Average True Range (ATR) | 1.04 | 0.32 |
| MACD | 0.14 | 0.02 |
| Stochastic Oscillator | 97.77 | 47.13 |
Bandwidth Inc is cloud-based communications platform-as-a-service (CPaaS) provider that enables enterprises to create, scale and operate voice or messaging communications services across any mobile application or connected device. Company earns revenue through the sale of communications services offered through Application Programming Interface software solutions to enterprise customers. The majority of the company's revenue is generated from usage-based fees that includes voice communication and messaging communication that traverse the platform and network.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.